.png)
Fatigue Evaluation & Treatment: For Clinicians
Updated: 51 minutes ago
This post outlines a practical framework for evaluating and managing Sjogren's fatigue, an essential but often neglected component of care. This page is for educational purposes only. It is not exhaustive, not an official guideline, and does not constitute medical advice. Tips for patients reading this post can be found here.
Why Fatigue Care is Essential
Fatigue is a core systemic feature of Sjogren’s disease, affecting 70% to 90% of patients. Often extreme, it can have a devastating impact on patients’ lives. Despite being primarily biological rather than psychological in origin, treatable drivers of fatigue are frequently missed.
Standard laboratory tests and traditional research tools do not predict fatigue severity. Fatigue does not correlate with ESSDAI scores, dryness, antibody titers, CRP, or ESR. Notably, fatigue is documented to be more severe, on average, in SSA-negative patients. See 10 Myths About Sjogren’s fatigue for more information and citations.
What Causes Sjogren’s fatigue?
Sjogren's fatigue is almost always multifactorial, typically driven by one or more of the following:
Immune dysregulation and inflammation (paradoxically correlated with the downregulation (204) of specific inflammatory pathways)
Organ-specific manifestations (such as lung disease or autonomic neuropathy)
Co-morbidities (such as autoimmune thyroid disease or iron deficiency)
Fatigue unrelated to Sjogren’s is not covered on this page but should always be considered.
RESOURCES
Practical Tips for Fatigue Care
1. Treat What Is Treatable, but First You Must Look for it.
Fatigue assessment should be incorporated into routine care. Each patient is unique, and underlying drivers, often multiple, can change over time. In addition to routine screening, specific symptom patterns can help guide targeted evaluations, which is the topic of an upcoming post. For instance, shortness of breath on exertion, muscle weakness, and orthostatic intolerance can all lead to fatigue and loss of function but call for different approaches.
2. Identify and Treat Overlooked Drivers of Fatigue.
The underlying causes of Sjogren’s-related fatigue are often not clinically obvious without methodical, targeted screening. Priority areas for evaluation and treatment include:
Common Comorbidities: Iron deficiency, celiac disease, liver disease, sleep disorders such as obstructive sleep apnea, and autoimmune thyroid disease. Common comorbid rheumatic diseases include rheumatoid arthritis, lupus, systemic sclerosis, psoriatic arthritis, and axial spondylitis. Treating comorbidities can reduce the overall burden of disease, including fatigue.
Organ, Neurological, and Hematological Manifestations:
Lung disease, which is not limited to interstitial lung disease (ILD), affects about half of patients. Baseline screening tests for all patients are recommended in the Sjogren's Foundation Clinical Practice Guidelines for Pulmonary Disease.
Kidney Disease: Routine blood and urine screening can identify renal involvement, especially distal renal tubular acidosis (dRTA), which is often unrecognized in its early stages. How My Doctors Monitor My Sjogren’s provides an example of comprehensive monitoring, including screening tests for dRTA.
Anemia: A routine complete blood count (CBC) can point to various underlying types of anemia.
Migraines and other severe headaches affect about half of patients (291). Patients may not volunteer their headache history, leading to missed opportunities for diagnosis and targeted treatment.
Neuropathy: Neuropathy symptoms affect up to 70% of patients when including small fiber neuropathy (SFN) and autonomic disorders, both of which are frequently missed or mistaken for fibromyalgia or anxiety.
Autonomic Disorders: Disorders of orthostatic intolerance (OI), such as Postural Orthostatic Tachycardia Syndrome (POTS) and orthostatic hypotension, are highly prevalent, treatable causes of severe fatigue and cognitive dysfunction (brain fog). Because these conditions reduce cerebral blood flow, symptoms worsen with upright posture. See the POTS page for PDF instructions on a simple 10-minute stand test (3 minutes is insufficient) for home or office use.
RESOURCES
Autonomic Disorders/POTS to links to a step-by-step consensus guideline for evaluation and management.
Dysautonomia/POTS page for resources, including CME lectures.
3. Individualize Evaluation and Treatment.
Sjogren's is a highly heterogeneous disease. Most patients experience a foundational fatigue burden driven by immune and inflammatory dysregulation, combined with more easily identifiable causes listed in Sections 1 and 2 above.
Because there is no single cause or biomarker that correlates with fatigue severity, clinicians must cast a wide net and conduct ongoing evaluations to address it effectively. Even when a specific etiology of fatigue is identified, underlying biological mechanisms vary, leading patients with similar symptoms to respond differently to the same intervention.
Because Sjogren's research has lagged decades behind diseases like lupus and rheumatoid arthritis, care currently relies on treatments adapted from other conditions. Emerging Sjogren's-specific therapies promise more targeted options, but existing interventions, including hydroxychloroquine, can still provide significant relief. Finding the right management strategy often requires patience, curiosity, and a structured trial-and-error process.
What about non-conventional therapies?
Case studies and clinical reports suggest that some patients benefit from treatments such as low-dose naltrexone (LDN), GLP-1 receptor agonists, or stimulants like methylphenidate and modafinil. Because of the profound disability caused by extreme Sjogren's fatigue, many patients are willing to try low-risk, options that have not been through rigorous clinical trials when treatments prove insufficient.
Treat what is treatable! You do not need to wait for emerging treatments to be approved to make a meaningful difference. Existing interventions can provide significant relief.
TREATMENT RESOURCES
Hydroxychloroquine (HCQ II) -Why treat Sjogren’s Learn what the research shows about HCQ in Sjogren's care, and why relying on a single, poorly designed randomized controlled trial is inadequate for guiding real-world treatment decisions.
Sjogren’s Advocate Resources page, Treatments- Find detailed resources, including Dr Kara Wada’s, 2026 Sjogren’s Treatments and Trials Map
4. Do not Forget Prevention.
Chronic and recurrent infections, especially SARS-CoV-2 (COVID-19), can push the immune system into overdrive, triggering new autoimmune diseases or autonomic disorders while exacerbating fatigue and cognitive dysfunction. People with autoimmune rheumatic diseases, especially Sjogren's, are at higher risk of developing Long COVID.
Staying up to date on vaccines can reduce risk, but wearing high-quality N95 masks in indoor public settings remains key to preventing airborne infections like Covid, flu, RSV and measles.
Communication Dos and Don’ts
Do's
Ask about fatigue proactively, even if the patient does not bring it up. Patients often stop reporting severe fatigue because they have faced dismissive comments, psychological and functional labels, or were told nothing could be done.
People with Sjogren’s often feel abandoned by providers, family, and friends who disbelieve or blame them for their symptoms. Over time, they stop asking for help and quietly resign themselves to a diminished life, sacrificing careers, social ties, and basic daily activities.
Believe patients and let them know you take their fatigue seriously. This is crucial, even if you do not have obvious answers. Most patients appreciate comments like: “I don’t know, but let’s work together to figure this out”.
Check in routinely regarding fatigue symptoms, patterns, and function. Be as specific as possible such as asking about the impact on employment, home life, and activities of daily living. Note limits on standing tolerance, necessary rest before and after activities, and functional hours per day.
An upcoming practical worksheet will provide patients with a structured tool to share their symptom history succinctly with clinicians.
Ask about specific types of fatigue. The approach to orthostatic intolerance differs from the approach to shortness of breath on exertion, which differs from the approach to muscle weakness.
Recommend exercise within the envelope of tolerance. Patients with autonomic disorders or inflammatory arthritis often need symptom management before increasing activity
Exercise can sometimes be harmful, especially for patients with recent infections, unresolved long COVID symptoms, or comorbid ME/CFS.
Discuss realistic expectations. Small wins matter. A realistic goal is maximizing function and quality of life rather than expecting full symptom resolution. Increasing from four to five functional hours a day represents a tangible improvement.
Don'ts
Do not tell patients that their fatigue is unrelated to Sjogren's because of low disease activity, negative autoantibodies, or normal inflammatory markers. Biological drivers of fatigue often do not correlate with standard systemic activity scores or routine lab results. See 10 Myths About Sjogren’s Fatigue to learn more.
Do not tell patients there is nothing you can do. See Treatment Resources in Section 3.
Do not tell patients hydroxychloroquine (HCQ) does not work for Sjogren’s and does not help fatigue. See HCQ II and HCQ III for current research on the risks and benefits of HCQ in Sjogren’s.
Do not tell patients that if they just lose weight, reduce stress or adopt a can-do attitude, they will improve. While lifestyle habits can support general health, Sjogren's fatigue is not normal tiredness that responds to lifestyle measures in the same way that healthy people do.
Telling a patient to push through fatigue without a tailored plan is a recipe for a crash. You cannot kale, yoga, or brain train your way out of Sjogren’s fatigue.
Do not default to diagnostic labels like fibromyalgia, menopause, functional disorders, deconditioning, or psychological distress. Using these labels as catch-all explanations cuts off evaluation for treatable physical causes of fatigue and destroys patient trust.
Patients who develop anxiety or depression due to the devastating impact of chronic illness and the struggle to find informed care are frequently told their fatigue is caused by emotional distress, when the distress is often primarily caused by the inability to find symptom relief or clinicians who know how to help them.
RESOURCE:
For more detailed communication strategies, see Table 1, "Never-words, their impact, and suggested alternatives" in the article by Smyth and Blitshteyn, Language Matters: What Not to Say to Patients with Long COVID, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, and Other Complex Chronic Disorders (293).
Comments